Linked Life Data

12838451

Source:http://linkedlifedata.com/resource/pubmed/id/12838451

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2003-7-2
pubmed:abstractText
Mitoxantrone is an antineoplastic agent that exerts a potent immunosuppresive effect, including suppression of B cell immunity and reduction of T cell numbers. Clinical trials have shown that mitoxantrone has a statistically significant impact on reduction of relapse rate and delays disability progression in patients with relapsing remitting (RR) multiple sclerosis (MS) or secondary progressive (SP) MS. Treatment is well tolerated, but the risk of cardiotoxicity at higher cumulative doses is likely to limit the duration of treatment. The maximum cumulative dose recommended is 140 mg/m2. In 2000, the FDA (Food and Drug Administration) approved the use of mitoxantrone for the treatment of active RRMS, SPMS and progressing relapsing (PR) MS.
pubmed:language
spa
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0213-4853
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
318-23
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
[Mitoxantrone].
pubmed:affiliation
Unidad de Neuroinmunología Clínica, Escuela de Enfermería, Hospital Universitario Vall d'Hebron Barcelona, Spain. imma@comg.es
pubmed:publicationType
Journal Article, English Abstract, Review